Valion Bio (VBIO) Net Cash Flow (2021 - 2025)
Valion Bio (VBIO) posted quarterly Net Cash Flow of $9.2 million for Q4 2025, up 1751.21% year-over-year from $496000.0 in Q4 2024, and up 305.92% quarter-over-quarter from $2.3 million in Q3 2025.
Valion Bio (VBIO) Net Cash Flow (2021 - 2025) Analysis & Trends
Valion Bio's Net Cash Flow history runs 5 years deep, the most recent figure standing at $9.2 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 1751.21% year-over-year to $9.2 million; the TTM figure through Dec 2025 stood at $10.6 million (up 1518.93% YoY), while the FY2025 annual figure was $10.6 million, up 1518.93% from the prior year.
- Net Cash Flow for Q4 2025 stood at $9.2 million, up from $2.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $12.1 million in Q4 2021, with the low at -$2.8 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$609500.0 (2021), against an average of $609350.0.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 396.85% in 2022, then jumped 1751.21% in 2025.
- Valion Bio's Net Cash Flow stood at $12.1 million in 2021, then tumbled by 123.11% to -$2.8 million in 2022, then surged by 35.39% to -$1.8 million in 2023, then jumped by 127.39% to $496000.0 in 2024, then surged by 1751.21% to $9.2 million in 2025.
- Business Quant data shows VBIO's Net Cash Flow at $9.2 million in Q4 2025, $2.3 million in Q3 2025, and $542000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.18 Mn |
| Dec 31, 2025 | 9.18 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 542,000.00 |
| Jun 30, 2025 | 542,000.00 |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | 496,000.00 |
| Dec 31, 2024 | 496,000.00 |
| Sep 30, 2024 | -1.54 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | 2.58 Mn |
| Sep 30, 2023 | 2.58 Mn |